PRNewsWire
22 Sept 2026, 10:36 UTC · 1h ago
Verdict
Headline leans bearish. We score CAPR −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
The FDA advisory committee voted 9-3 that available evidence did not support the efficacy of Deramiocel for DMD-associated cardiomyopathy.
Priced inreported on July 30, 2026
More negative than 99% of claims this week
The FDA raised concerns regarding post-hoc changes to the statistical analysis plan for the primary endpoint, PUL 2.0, shortly before database unblinding.
Priced in
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
A class action lawsuit has been filed against Capricor Therapeutics for securities fraud following a 64.5% stock drop on July 27, 2026.
Newpress release dated Sep 22, 2026
So whatLegal settlements or judgments from this suit could impact the company's cash runway and necessitate additional financing or dilution.
More negative than 79% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud class action lawsuit following a massive stock drop and FDA concerns regarding clinical data integrity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
6h ago
—
CAPR hasn't traded since this ran. Last close $8.90 (Sep 21); the reaction starts at the next open.
CAPR chart →